An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease
Overview
- Phase
- Early Phase 1
- Intervention
- CS-206
- Conditions
- Sickle Cell Disease
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- AEs(Adverse Events) and SAEs(Serious Adverse Events) after CS-101 infusion
- Status
- Recruiting
- Last Updated
- 2 months ago
Overview
Brief Summary
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Detailed Description
CS-101 is an autologous CD34+ cell suspension, edited by in vitro base editing technology, which modifies the BCL11A binding site in HBG promoter, so that it loses the ability to bind to BCL11A, which can re-induce the production of γ-globin chain and increase the concentration of fetal hemoglobin(HbF) in the blood, compensating for the function of missing adult hemoglobin HbA to achieve clinical cure. The therapy addresses two major challenges in the current treatment of the disease: lack of matching donors and graft-versus-host diseases in allogeneic hematopoietic stem cell transplantation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants must be between 12 to 35 years old (inclusive). Participants or their legal guardians (for participants below 18 years old) must provide written informed consent before any study-related procedures.
- •Participants must have a Documented βS/βS, βS/β0 or βS/β+ genotype.
- •Participants must have at least one of the following conditions
- •At least 2 occurrences of any of the following events within 2 years prior to screening.
- •Acute pain crisis: requiring a visit to a medical facility and administration of pain medications (opioids or intravenous NSAIDs) or red blood cell transfusions.
- •Acute chest syndrome: defined by the presence of a new pulmonary infiltrate on a chest X-ray, associated with pneumonia-like symptoms, including chest pain, fever, or respiratory distress.
- •Priapism lasting more than 2 hours and necessitating a visit to a medical facility for intervention.
- •Stroke or transient ischemic attack (TIA): confirmed by imaging studies (e.g., MRI or CT scan), including silent stroke, and overt stroke leading to neurological deficits lasting \>24 hours.
- •Presence of red cell alloimmunization (\>2 antibodies) and the need for ongoing chronic transfusions.
- •Participants who have failed, not tolerated, refused the standard of care for Sickle Cell Disease (SCD), or are unable to access the standard of care due to the availability
Exclusion Criteria
- •Female participants who are pregnant, breastfeeding, or planning pregnancy during the study period are excluded.
- •Participation in another investigational drug trial within 30 days prior to screening or within 5 half-lives (whichever is longer).
- •Subjects who have received or are receiving luspatercept treatment within 3 months prior to screening.
- •Subjects who have previously received any gene therapy for the disease.
- •Subjects with a fully matched related donor who are already scheduled for allogeneic hematopoietic stem cell transplantation.
- •More than 10 unplanned hospitalizations or emergency visits within 12 months prior to screening, which the investigator believes are related to significant chronic pain rather than acute pain crisis (VOC).
- •Severe liver dysfunction:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3× the upper limit of normal (ULN) or:
- •International Normalized Ratio (INR) \>1.5× ULN
- •Severe renal impairment (creatinine clearance \<30 mL/min/1.73 m²) are excluded.
Arms & Interventions
CS-206
Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Intervention: CS-206
Outcomes
Primary Outcomes
AEs(Adverse Events) and SAEs(Serious Adverse Events) after CS-101 infusion
Time Frame: From signing informed consent to 24 months post-CS-206 infusion
Frequency and severity of adverse events(AEs）as assessed by CTCAE(Common Terminology Criteria for Adverse Events)v5.0
Incidence of transplant-related mortality
Time Frame: From baseline to 100 days and 12 months post-CS-206 infusion
Incidence of transplant-related mortality(Transplant-related mortality events defined as deaths assessed by the investigator as potentially transplant-related)
Time to neutrophil engraftment
Time Frame: Up to 24 months post-CS-206 infusion
Time to neutrophil engraftment is defined as first day of 3 consecutive measurements of absolute neutrophil count≥0.5×10\^9/L on three different days.
Time to platelet engraftment
Time Frame: Up to 24 months post-CS-206 infusion
Time to platelet engraftment is defined as first day of 3 consecutive measurements of absolute platelet count≥20×10\^9/L on three different days and without platelet transfusion.
All-cause mortality
Time Frame: Up to 24 months post-CS-206 infusion
Free from severe VOCs for 12 consecutive months (VF12)
Time Frame: starting 60 days after the last red blood cell transfusion up to 24 months
Free from severe vaso-occlusive crises (VOCs) for 12 consecutive months (VF12)
Secondary Outcomes
- Free from hospitalization due to severe vaso-occlusive crises for 12 consecutive months(HF12)(starting 60 days after the last red blood cell transfusion up to 24 months)
- Free from severe VOCs for 9 consecutive months (VF9)(starting 60 days after the last red blood cell transfusion up to 24 months)
- Annualized incidence of severe vaso-occlusive crises (VOC)(starting 60 days after the last red blood cell transfusion up to 24 months)
- Annualized incidence of hospitalization due to severe vaso-occlusive crises(starting 60 days after the last red blood cell transfusion)
- HbF (fetal hemoglobin) level in blood samples(up to 24 months post-CS-206 infusion)
- Proportion of edited alleles in peripheral blood leukocytes and bone marrow cells, and persistence and chimerism kinetics evaluation(up to 24 months post-CS-206 infusion)